Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
1
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Background/Aims: Stereotactic body radiation therapy (SBRT) is used as an alternative ablative treatment in patients with hepatocellular carcinoma (HCC) not suitable for curative treatments. The purpose of this prospective study was to evaluate the long-term efficacy of SBRT for small (≤5 cm) HCCs. Methods: A phase II, single-arm clinical trial on SBRT for small HCCs was conducted at an academic tertiary care center. The planned SBRT dose was 45 Gy with a fraction size of 15-Gy over 3 consecutive days. The primary endpoint was 2-year local control rate. Radiologic responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and the modified RECIST criteria. Results: Between 2013 and 2016, 50 patients (53 lesions) were enrolled, with a median follow-up period of 47.8 months (range, 2.9–70.6). Patients’ age ranged from 41 to 74 years, and 80% were male. Median tumor size was 1.3 cm (range, 0.7–3.1). The 2- and 5-year local control rates were 100% and 97.1%, respectively. The 5-year overall survival rate was 77.6%. Six months after SBRT, radiologic responses were evident in 44 lesions (83%) according to the RECIST criteria and 49 (92.4%) according to the modified RECIST criteria. None of the patients showed grade ≥3 adverse events. Conclusions: SBRT showed excellent results as an ablative treatment for patients with small HCCs while showing minimal toxicities. SBRT can be a good alternative for both curative and salvage intents in patients with HCCs that are unsuitable for curative treatments.
Abstract
Background/Aims: Stereotactic body radiation therapy (SBRT) is used as an alternative ablative treatment in patients with hepatocellular carcinoma (HCC) not suitable for curative treatments. The purpose of this prospective study was to evaluate the long-term efficacy of SBRT for small (≤5 cm) HCCs. Methods: A phase II, single-arm clinical trial on SBRT for small HCCs was conducted at an academic tertiary care center. The planned SBRT dose was 45 Gy with a fraction size of 15-Gy over 3 consecutive days. The primary endpoint was 2-year local control rate. Radiologic responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and the modified RECIST criteria. Results: Between 2013 and 2016, 50 patients (53 lesions) were enrolled, with a median follow-up period of 47.8 months (range, 2.9–70.6). Patients’ age ranged from 41 to 74 years, and 80% were male. Median tumor size was 1.3 cm (range, 0.7–3.1). The 2- and 5-year local control rates were 100% and 97.1%, respectively. The 5-year overall survival rate was 77.6%. Six months after SBRT, radiologic responses were evident in 44 lesions (83%) according to the RECIST criteria and 49 (92.4%) according to the modified RECIST criteria. None of the patients showed grade ≥3 adverse events. Conclusions: SBRT showed excellent results as an ablative treatment for patients with small HCCs while showing minimal toxicities. SBRT can be a good alternative for both curative and salvage intents in patients with HCCs that are unsuitable for curative treatments.
참고문헌 (31)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- 김보현, "Epidemiology of liver cancer in South Korea", Clinical and Molecular Hepatology, 24(1), pp.1~9 (2018), 대한간학회
- Valery PC, "Projections of primary liver cancer to 2030 in 30 countries worldwide", Hepatology, 67, pp.600~611 (2018)
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
- Feng M, "Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage : a phase 2 clinical trial", JAMA Oncol, 4, pp.40~47 (2018)
- Kang JK, "Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization", Cancer, 118, pp.5424~5431 (2012)
- Sanuki N, "Stereotactic body radiotherapy for small hepatocellular carcinoma : a retrospective outcome analysis in 185 patients", Acta Oncol, 53, pp.399~404 (2014)
- Takeda A, "Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation", Cancer, 122, pp.2041~2049 (2016)
- Yoon SM, "Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma", PLoS One, 8, pp.e79854~ (2013)
- Bibault JE, "Stereotactic body radiation therapy for hepatocellular carcinoma : prognostic factors of local control, overall survival, and toxicity", PLoS One, 8, pp.e77472~ (2013)
- Su TS, "Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients", J Surg Oncol, 113, pp.181~187 (2016)
- Takeda A, "Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma", J Gastroenterol Hepatol, 29, pp.372~379 (2014)
- Andolino DL, "Stereotactic body radiotherapy for primary hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 81, pp.e447~e453 (2011)
- Bujold A, "Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma", J Clin Oncol, 31, pp.1631~1639 (2013)
- Bruix J, "Management of hepatocellular carcinoma : an update", Hepatology, 53, pp.1020~1022 (2011)
- Jung J, "Radiationinduced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma : clinical and dose-volumetric parameters", Radiat Oncol, 8, pp.249~ (2013)
- Jeong Y, "Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma", BMC Cancer, 18, pp.416~ (2018)
- Jung J, "Targeting accuracy of image-guided stereotactic body radiation therapy for hepatocellular carcinoma in real-life clinical practice : in vivo assessment using hepatic parenchymal changes on Gd-EOB-DTPAenhanced magnetic resonance images", Int J Radiat Oncol Biol Phys, 102, pp.867~874 (2018)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Tse RV, "Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma", J Clin Oncol, 26, pp.657~664 (2008)
- Kubo K, "Long-term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma", Hepatol Res, 48, pp.701~707 (2018)
- Kwon JH, "Longterm effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer", BMC Cancer, 10, pp.475~ (2010)
- 이경화, "Is higher dose always the right answer in stereotactic body radiation therapy for small hepatocellular carcinoma?", Radiation oncology journal, 36(2), pp.129~138 (2018), 대한방사선종양학회
- Kim YS, "Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma : analysis of prognostic factors", J Hepatol, 58, pp.89~97 (2013)
- Shiina S, "Radiofrequency ablation for hepatocellular carcinoma : 10-year outcome and prognostic factors", Am J Gastroenterol, 107, pp.569~577 (2012)
- Hara K, "Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation : a propensity score analysis", Hepatology, 69, pp.2533~2545 (2019)
- Sapir E, "Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 100, pp.122~130 (2018)
- Su TS, "Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 98, pp.639~646 (2017)
- Wahl DR, "Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma", J Clin Oncol, 34, pp.452~459 (2016)